Prior authorization required for listed Factor VIII products

Prior authorization is required for the listed human and recombinant factor VIII products; approval is contingent on meeting the policy's initial or continued therapy criteria (diagnosis, hematology involvement, appropriate indication, documentation of body weight in kg, and dosing within FDA maximums).

• Requests must meet all applicable initial or continuation criteria in Section I or II of the policy (diagnosis, prescriber specialty, indication, prophylaxis-specific conditions, desmopressin consideration, Jivi age/treatment history, weight documentation, and FDA dose limits).

Reference HCPCS codes on prior authorization requests

When requesting prior authorization or submitting claims, reference the HCPCS codes listed in the policy (examples below) so the request aligns with the product billed.

• J7182, J7185, J7188, J7190, J7191, J7192, J7204, J7205, J7207, J7208, J7209, J7210, J7211

HCPCS codes listed (informational)

HCPCS codes for recombinant and related Factor VIII products are provided for informational purposes; providers should verify plan-specific billing rules before submission.

• Codes listed include unit-based HCPCS codes for specific products and 'not otherwise specified' codes; inclusion in the list does not by itself ensure coverage.

Desmopressin trial required when FVIII activity > 5%

If a patient's factor VIII coagulant activity level is > 5%, desmopressin acetate should be used prior to factor VIII products unless it is contraindicated, causes clinically significant adverse effects, or an appropriate formulation is unavailable.

• Desmopressin dosing examples and routes are provided in Appendix (e.g., IV 0.3 mcg/kg every 48 hours; nasal spray dosing per label).

Provide clinical justification and specialty consultation

Include clinical details that support medical necessity and product selection as described in the policy. Provide hematology consultation notes, justification for product choice, and evidence of prior therapies when applicable.

• For Jivi requests, document patient age (≥12 years) and prior treatment history per policy.
• For routine prophylaxis requests, document prior prophylaxis use, severe hemophilia status (FVIII <1%), or history of a serious spontaneous bleed when required.

Document reasons if desmopressin not used

When desmopressin is not used because of contraindication, adverse effects, or unavailability, document the reason in the clinical record submitted with the request.

• If desmopressin failed, include documentation of failure or adverse effects; if unavailable, note formulation supply issue.

Required clinical documentation for authorization

Provider must submit documentation (office chart notes, lab results, or other clinical information) demonstrating that the member meets all applicable approval criteria.

• Include diagnosis (congenital vs acquired hemophilia A), hematologist involvement, body weight in kg, relevant factor VIII activity levels, and prior treatment history.
• For prophylaxis requests, include documentation supporting prior prophylaxis use or severity/spontaneous bleed history when applicable.

Cite prescribing information and clinical guidelines

Use prescribing information and national guidelines cited in the policy to support dosing and clinical rationale in the authorization request and medical record.

• References include product Prescribing Information (Advate, Adynovate, Afstyla, Jivi, etc.) and hemophilia management guidelines (e.g., Srivastava et al., MASAC recommendations).

Documentation and coding guidance to include with requests

Follow up-to-date coding guidance and the Health Plan's coverage documents, state and federal requirements, and Health Plan administrative policies when submitting claims or prior authorization requests.

• Codes referenced in the policy are informational; verify professional coding sources before claim submission.
• Ensure submitted codes match the product and units administered per HCPCS descriptions.

Denial risk for non‑FDA or off‑label indications

Requests for non–FDA‑approved indications not addressed in this policy may be denied unless sufficient documentation is provided in accordance with the Health Plan's off‑label use policy.

• Refer to off‑label use policy CP.PMN.53 (Medicaid) for required evidence when requesting coverage for non‑FDA indications.

Coding mismatch may cause denial

Claims or authorization requests may be denied or coverage not guaranteed if coding does not match the HCPCS codes listed in the policy or if professional coding guidance is not followed.

• Ensure the HCPCS code selected corresponds to the exact product and per‑IU billing convention described in the policy (unit‑based HCPCS codes).

Code lists do not guarantee coverage

Inclusion or exclusion of any HCPCS or other codes in this policy does not guarantee coverage; providers must confirm current professional coding guidance prior to claim submission.

• Use the policy's code list only as a reference and verify with up‑to‑date coding sources and payer instructions.

Apply dosing guidance across care settings

Dosing and administration guidance in the policy applies across care settings — home infusion, infusion center, and perioperative/hospital settings — depending on the clinical scenario and product labeling.

• Select setting‑appropriate dosing and monitoring per product labeling and clinical need.